1. Parolaro D, Massi P, Rubino T, and Monti E (2002) Endocannabinoids in the immune system and cancer: endocannabinoids in the immune system and cancer. Prostaglandins Leukotrienes Essent Fatty Acids 66: 319-332.
Guzmán M, Sanchez C, and Galve-Roperh I (2002) Cannabinoids and cell fate. Pharmacol Ther 95: 175-184
Patsos HA, Hicks DJ, Greenhough A, Williams AC, and Paraskeva C (2005) Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 33: 712-714
Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, and Guzman M (2004) Hypothesis: cannabinoid therapy for the treatment of gliomas. Neuropharmacology 47: 315-323.
Ligresti A, Schiano Moriello A, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, and Di Marzo V (2006b) Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther, in press.
Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, and Guzman M (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Investig 111: 43-50
Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, and Bifulco M (2003) Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17: 1771-1773.
2. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, and Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97: 9561-9566.
3. Mechoulam R (1986) The pharmacohistory of cannabis sativa, in Cannabis as Therapeutic Agent (Mechoulam R ed) pp 1-19, CRC Press, Boca Raton, FL.
4. Iversen LL (2000) The Science of Marijuana. Oxford University Press, Oxford, UK.
5. Fox A and Bevan S (2005) Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs 14: 695-703.
6. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, and James I (2001) The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100.
Guindon J, De Lean A, and Beaulieu P (2006) Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 121: 85-93.
Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Hogestatt ED, Meng ID, and Julius D (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature (Lond) 427: 260-265.
8. Williams IJ, Edwards S, Rubo A, Haller VL, Stevens DL, and Welch SP (2006) Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta(9)-tetrahydrocannabinol. Eur J Pharmacol 539: 57-63.
9. Ware M and Beaulieu P (2005) Cannabinoids for the treatment of pain: an update on recent clinical trials. Pain Res Manag 10: 27A-30A.
Burns TL and Ineck JR (2006) Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 40: 251-260.
